In an experimental study published in the scientific journal Gut, the investigators demonstrated that specific bacterial drivers of intestinal inflammation could be selectively inhibited in animal and cell models without broadly disrupting the surrounding gut microbiome.

However, because the community of microorganisms varies widely from person to person, researchers have faced substantial hurdles in determining which specific bacteria actively drive inflammatory responses rather than simply multiplying as a secondary consequence of intestinal disease.

To pinpoint disease-promoting microorganisms in individual patients, the researchers analyzed and compared stool samples collected from patients before and after therapeutic interventions, specifically antibiotics or fecal microbiota transplantation. Gut microorganisms harvested from these patient samples were transferred into germ-free laboratory mice to assess their functional impact on intestinal inflammation. The scientific team then utilized host-derived antibodies produced by the immune system to isolate potentially harmful bacteria and evaluate their inflammatory activity.

Through this screening pipeline, the investigators identified two distinct bacterial species capable of initiating or worsening intestinal inflammation in susceptible hosts: Sarcina perfringens and Hathewaya massiliensis. Mechanistic evaluations demonstrated that both bacterial species activate cells of the host innate immune system, thereby stimulating localized inflammatory responses.

Subsequent analyses of international patient datasets revealed that Sarcina perfringens was present at elevated levels in approximately 25 to 30 percent of patients with inflammatory bowel disease, whereas Hathewaya massiliensis was elevated in approximately five percent of analyzed cases. Complementary experiments using human intestinal organoids—miniature three-dimensional tissue cultures generated from human cells—confirmed that these bacteria drive inflammation through immune activation and impair the normal barrier function of intestinal epithelial cells.

“Inflammatory bowel disease does not have the same triggers in every patient. Our findings show that we can specifically identify bacteria that contribute to inflammation in individual patients. This is an important step towards more personalized treatment,” explained Dr. Lukas Mager, emphasizing that the heterogeneity of bacterial triggers necessitates patient-specific diagnostic and therapeutic approaches.

Rather than relying on non-selective broad-spectrum antibiotics, the research team screened a library of 1,518 previously approved compounds to find targeted alternatives. This screening identified five chemical agents capable of selectively inhibiting the growth of both target bacterial species without causing substantial collateral disruption to other common, beneficial gut bacteria.

Among the identified candidates, the antibacterial compound oxolinic acid demonstrated notable efficacy in experimental validation. In a mouse model, oxolinic acid reduced intestinal inflammation driven by Sarcina perfringens with an efficacy comparable to the conventional broad-spectrum antibiotic metronidazole. However, unlike metronidazole, oxolinic acid exerted only a minor impact on the broader bacterial community examined, indicating that selective suppression of specific pathobionts while preserving overall microbiota integrity is experimentally achievable.

Current clinical interventions for inflammatory bowel disease concentrate primarily on suppressing host immune responses, but targeted antimicrobial approaches could complement these regimens by eliminating underlying bacterial triggers. The authors noted that further research remains essential before this approach can be introduced into clinical practice, particularly to confirm whether targeted inhibition of these specific bacteria is safe and effective in human patients.

The peer-reviewed experimental study, published on November 12, 2026, in the journal Gut under the title “Identification and selective inhibition of patient-specific pathobionts in inflammatory bowel disease” (DOI: 10.1136/gutjnl-2026-339262), was conducted through a cross-border collaboration between German and Canadian institutions. Research in Germany was centered at University Hospital Tübingen and the Faculty of Medicine at the University of Tübingen, with substantial contributions from Mahana Sabachvili, the M3 Research Center, the Department of Internal Medicine I, and the Clusters of Excellence CMFI and iFIT. In Canada, key contributions were made by Spencer Abbott and Carolyn Thomson at the University of Calgary. The work received financial support from several organizations, including the European Research Council through Dr. Lukas Mager’s Starting Grant SOAR.

Subject of Research: Targeted identification and selective inhibition of inflammation-promoting gut bacteria in inflammatory bowel disease

Article Title: Inflammatory bowel disease: a new approach to personalized therapies

Article References: Inflammatory bowel disease: a new approach to personalized therapies. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: inflammatory bowel disease, gut microbiome, Sarcina perfringens, Hathewaya massiliensis, oxolinic acid, intestinal inflammation, metronidazole, fecal microbiota transplantation, germ-free mice, intestinal organoids, pathobionts, innate immune system, epithelial barrier function, personalized medicine, University Hospital Tübingen, University of Calgary